{"id":1278,"date":"2020-07-22T10:59:14","date_gmt":"2020-07-22T10:59:14","guid":{"rendered":"https:\/\/ceamedsa.com\/?page_id=1278"},"modified":"2020-07-23T08:39:46","modified_gmt":"2020-07-23T08:39:46","slug":"ceameds-proposal-for-covid-19","status":"publish","type":"page","link":"https:\/\/ceamedsa.com\/en\/ceameds-proposal-for-covid-19\/","title":{"rendered":"CEAMED&#8217;s proposal for COVID-19"},"content":{"rendered":"<p>CEAMED has been developing small molecule inhibitors of STAT3 as possible treatments for Triple Negative Breast Cancers (TNBCs), whose development and metastasis are believed to be driven by STAT3 activation.<\/p>\n<p>CEAMED has various families of compounds that reduce the levels of IL-6 activated STAT3, with cellular IC50 values between 50 y 1000 nM (for comparison Silibinin has an IC50 of approximately 100 mM)<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-1279 aligncenter\" src=\"https:\/\/ceamedsa.com\/wp-content\/uploads\/2020\/07\/inhibition-STAT3-CEAMED-compounds.png\" alt=\"Inhibition STAT3 CEAMED compounds\" width=\"515\" height=\"288\" srcset=\"https:\/\/ceamedsa.com\/wp-content\/uploads\/2020\/07\/inhibition-STAT3-CEAMED-compounds.png 515w, https:\/\/ceamedsa.com\/wp-content\/uploads\/2020\/07\/inhibition-STAT3-CEAMED-compounds-300x168.png 300w, https:\/\/ceamedsa.com\/wp-content\/uploads\/2020\/07\/inhibition-STAT3-CEAMED-compounds-24x13.png 24w, https:\/\/ceamedsa.com\/wp-content\/uploads\/2020\/07\/inhibition-STAT3-CEAMED-compounds-36x20.png 36w, https:\/\/ceamedsa.com\/wp-content\/uploads\/2020\/07\/inhibition-STAT3-CEAMED-compounds-48x27.png 48w\" sizes=\"auto, (max-width: 515px) 100vw, 515px\" \/><\/p>\n<p>Advanced candidate, CM-978:<\/p>\n<ul>\n<li>Potent inhibitor of the activation of STAT3 by IL-6 in human cells (IC50 ~ 0.6\u00a0\u00b5M).<\/li>\n<li>It has a good half-life, volume of distribution and bioavailability after PO or IP dosing, in both mice and rats.<\/li>\n<\/ul>\n<p><strong>Given its cellular activity against IL-6 activated STAT3, and it\u2019s in vivo profile in rodents, CM-978 is a good candidate for additional in vitro and in vivo studies in order to determine whether an inhibitor of STAT3 is capable of preventing or reducing the effects of the cytokine storm produced by SARS-CoV-2.<\/strong><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>CEAMED is therefore looking for collaborators\/partners to help us further investigate these ideas.\u00a0 <\/strong><\/p>\n<ul>\n<li>Low toxicity in rats after 21 days repeated dosing.<\/li>\n<\/ul>\n<p>Related downloads:<\/p>\n<ul>\n<li><a  data-e-Disable-Page-Transition=\"true\" class=\"download-link\" title=\"\" href=\"https:\/\/ceamedsa.com\/en\/descarga\/1281\/?tmstv=1777121994\" rel=\"nofollow\" id=\"download-link-1281\" data-redirect=\"false\" >\n\tDossier CEAMED COVID-19 CM-978 (compound CM-978, as a potential agent for the treatment for COVID-19)\t(1592 downloads\t)\n<\/a>\n<\/li>\n<li><a  data-e-Disable-Page-Transition=\"true\" class=\"download-link\" title=\"\" href=\"https:\/\/ceamedsa.com\/en\/descarga\/1290\/?tmstv=1777121994\" rel=\"nofollow\" id=\"download-link-1290\" data-redirect=\"false\" >\n\tTriptych CEAMED COVID-19 (Investigational compounds to treat severe COVID-19)\t(1758 downloads\t)\n<\/a>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>CEAMED has been developing small molecule inhibitors of STAT3 as possible treatments for Triple Negative Breast Cancers (TNBCs), whose development and metastasis are believed to be driven by STAT3 activation. CEAMED has various families of compounds that reduce the levels of IL-6 activated STAT3, with cellular IC50 values between 50 y 1000 nM (for comparison &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/ceamedsa.com\/en\/ceameds-proposal-for-covid-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CEAMED&#8217;s proposal for COVID-19&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-1278","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/ceamedsa.com\/en\/wp-json\/wp\/v2\/pages\/1278\/"}],"collection":[{"href":"https:\/\/ceamedsa.com\/en\/wp-json\/wp\/v2\/pages\/"}],"about":[{"href":"https:\/\/ceamedsa.com\/en\/wp-json\/wp\/v2\/types\/page\/"}],"author":[{"embeddable":true,"href":"https:\/\/ceamedsa.com\/en\/wp-json\/wp\/v2\/users\/1\/"}],"replies":[{"embeddable":true,"href":"https:\/\/ceamedsa.com\/en\/wp-json\/wp\/v2\/comments\/?post=1278"}],"version-history":[{"count":3,"href":"https:\/\/ceamedsa.com\/en\/wp-json\/wp\/v2\/pages\/1278\/revisions\/"}],"predecessor-version":[{"id":1297,"href":"https:\/\/ceamedsa.com\/en\/wp-json\/wp\/v2\/pages\/1278\/revisions\/1297\/"}],"wp:attachment":[{"href":"https:\/\/ceamedsa.com\/en\/wp-json\/wp\/v2\/media\/?parent=1278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}